ABU DHABI 15 September 2020: The UAE has authorized the emergency use of the Covid19 vaccine; making it available to those first line defence heroes, who are most at risk of catching Covid-19, protecting them from any danger that they may be exposed to due to the nature of their work.
Abdul Rahman bin Mohammad bin Nasser Al Owais, Minister of Health and Prevention, stressed that this emergency use of the vaccine is fully and completely compatible with the regulations and laws that allow a faster review of licensing procedures.
Al-Owais confirmed that the results from the preclinical study, first and second phase trials showed that the vaccine is safe and effective. The third phase with a large number of volunteers is progressing very well. Studies related to the safety of vaccination were reviewed, and the process was carried out under the strict supervision of medical teams.
777 new cases
Dr. Omar Al Hammadi, official spokesperson for the UAE Government, announced that the UAE is still at the forefront of countries around the world in the number of total examinations in relation to the population; surpassing 8 million tests since the start of the pandemic.
It also announced 777 new cases of Covid-19, after 61,266 new examinations were performed, bringing the total number of confirmed cases to 80,266.
Al-Hammadi revealed that 530 recoveries were recorded, bringing the total number of recoveries to 69,981, and no deaths were recorded during the past 24 hours. Based on previous data, the number of patients still receiving treatment is 9,886.
31,000 vaccine volunteers
Dr. Nawal Al Kaabi, Head of the National Clinical Committee for Coronavirus and the principal investigator for the third phase of clinical trials of the Covid19 vaccine, said 31,000 volunteers from 125 nationalities participated in tests.
Al-Kaabi indicated that simple and expected side effects, like any other vaccine, were observed, most of which were reported as pain in the injection area, a feeling of fatigue and/or simple headaches, no serious side effects were recorded which required immediate treatment.
Al-Kaabi stressed that the initial results of the ongoing study show that the vaccine stimulates the production of antibodies and that the vaccine has been tried on 1,000 volunteers suffering from chronic diseases and no complications were observed.
Al-Kaabi said that the vaccine will be provided optionally to individuals working on the first line of defense as this group interacts with those infected and the vaccine will be available for specific groups optionally as well.